Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Zolbetuximab + CAPOX - (GLOW) | Claudin-18 isoform 2-positive (CLDN18.2)+, HER2‚àí, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
| Pfizer Inc. | Enzalutamide with docetaxel - (PRESIDE) | Metastatic castration-resistant prostate cancer | Phase 3 | Oral and intravenous | Oncology | |
| Pfizer Inc. | Aztreonam-avibactam (ATM-AVI) - (ASSEMBLE) | Serious Bacterial Infection | Phase 3 | Intravenous | Antibiotic | |
| Pfizer Inc. | Quadrivalent modified RNA (modRNA) | Influenza Vaccine | Phase 3 | Intramuscular | Immunology | |
| Pfizer Inc. | BHV-7000 | Focal Epilepsy | Phase 2/3 | Data Released | Oral | Neurology |
| Pfizer Inc. | BHV-8000 | Early Alzheimer's disease | Phase 2/3 | Ongoing | Oral | Neurology |
| Pfizer Inc. | BHV-8000 | Parkinson's disease | Phase 2/3 | Ongoing | Oral | Neurology |
| Pfizer Inc. | Bivalent BNT162b2 | Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
